- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
Paradigm, a specialty care management organization focused on delivering value-based solutions to improve outcomes for patients, payers, and providers, today announced that My Surgery has been ...
“Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results